This clinical trial focuses on patients with advanced Parkinson’s disease who experience motor fluctuations – periods when movement becomes more difficult as medication wears off. The study tests a new medication called IPX203, which contains two active substances: levodopa and carbidopa. These substances are already used to treat Parkinson’s disease, but IPX203 is a new modified-release capsule formulation that may work differently than existing treatments.
The purpose of the study is to compare IPX203 with standard immediate-release levodopa/carbidopa treatment to see if it can better improve the time when patients have good control of their movement symptoms. The medication will be given as capsules that patients take by mouth. The study will look at how well patients’ symptoms are controlled throughout the day and how long the medication’s effects last.
During the 12-week study, participants will be randomly assigned to receive either IPX203 or standard levodopa/carbidopa treatment. They will need to keep track of their symptoms in a diary and undergo regular evaluations to assess how well the treatment is working. The medication comes in different strength capsules to allow for proper dose adjustment based on individual patient needs.
Italy 
Poland 
Spain 
